SCHEMBL4375863

SCHEMBL4375863

C=CCn1c(C)cc(O)cc1=O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.62
LMNA P02545 2/20 0.48
KMT2A Q03164 5/20 0.47
MEN1 O00255 2/20 0.47
KDM4E B2RXH2 1/20 0.47
HPGD P15428 1/20 0.47
ALDH1A1 P00352 4/20 0.43
GAA P10253 2/20 0.43
TDP1 Q9NUW8 2/20 0.43
MAPT P10636 2/20 0.43
APLNR P35414 1/20 0.43
TSHR P16473 1/20 0.43
FPR1 P21462 1/20 0.43
CYP3A4 P08684 2/20 0.42
SMN1; SMN2 Q16637 3/20 0.41
NPC1 O15118 1/20 0.41
TP53 P04637 1/20 0.41
CYP2C19 P33261 1/20 0.41
RAB9A P51151 1/20 0.41
USP2 O75604 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14128779 0.78 CYP3A4 (0.56) POLBKMT2AMEN1KDM4EHPGD
SCHEMBL11427185 0.77 POLB (1.00) POLBLMNAKMT2AMEN1KDM4E
SCHEMBL10533292 0.75 KMT2A (0.47) POLBLMNAKMT2AMEN1KDM4E
SCHEMBL27229506 0.74 POLB (0.67) POLBLMNAKMT2AMEN1KDM4E
SCHEMBL13442334 0.73 KMT2A (0.47) POLBLMNAKMT2AMEN1KDM4E
SCHEMBL29022236 0.71 POLB (0.68) POLBLMNAKMT2AMEN1KDM4E
SCHEMBL4382205 0.71 KMT2A (0.51) POLBLMNAKMT2AMEN1KDM4E
SCHEMBL12080834 0.70 POLB (0.61) POLBLMNAKMT2AMEN1KDM4E
SCHEMBL2284503 0.70 KMT2A (0.50) POLBLMNAKMT2AMEN1KDM4E
SCHEMBL19151790 0.69 ALPG (0.51) POLBLMNAKMT2AMEN1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7629363-B2 antiinflammatory agent for treating asthma and chronic pulmonary inflammatory disease PFIZER INC (US) 2009-12-08 US disclosed
EP-1490064-B1 SUBSTITUTED PYRIDINONES AS MODULATORS OF P38 MAP KINASE PHARMACIA CORP (US) 2009-11-18 EP disclosed
US-7067540-B2 Substituted pyridinones PHARMACIA CORPORATION (US) 2006-06-27 US disclosed
US-20050176775-A1 Substituted pyridinones PHARMACIA CORPORATION 2005-08-11 US disclosed
WO-2005018557-A2 SUBSTITUTED PYRIDINONES PHARMACIA CORPORATION (US) 2005-03-03 WO disclosed
US-20040058964-A1 Substituted pyridinones PHARMACIA LLC 2004-03-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058964-A1 Substituted pyridinones MAPK1, MAPK6, MAPK7 POLB 1610/4885LMNA 1815/4885KMT2A 4674/4885
US-20050176775-A1 Substituted pyridinones MAPK1, MAPK6, MAP3K6 POLB 1676/4885LMNA 1884/4885KMT2A 4574/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.